Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Singer

Otolaryngology Brooklyn, NY Medical Doctor

NPI 1760658595 CMS profile 307324

134 Atlantic Ave, Brooklyn, NY 11201

Open in the dashboard

General payments

$39,375

37 records reported · program years 2019–2025

Research payments

$2,970

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,926 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Michael Singer of Brooklyn, NY is reported in the CMS Open Payments database as having received $39,375 across 37 general payments and $2,970 in research payments paid to them. Separately, studies naming them as principal investigator received $23,926 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,620 2
2024 General $3,446 5
2023 General $19,572 12
2022 General $1,526 4
2022 Research $2,970 1
2021 General $5,000 1
2020 General $2,100 4
2019 General $6,111 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Singer
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Michael Singer were reported at $1,620. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Michael Singer Otolaryngology median Middle half National median
2019 $6,111 $194 $82–$512 $163
2020 $2,100 $118 $42–$280 $114
2021 $5,000 $167 $63–$444 $132
2022 $1,526 $216 $84–$545 $149
2023 $19,572 $235 $93–$588 $160
2024 $3,446 $280 $111–$699 $164
2025 $1,620 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $26,163 23 payments
  2. Medtronic USA, Inc. $8,211 13 payments
  3. Amgen Inc. $5,000 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,125 15 payments
  2. Consulting Fee $17,835 11 payments
  3. Travel and Lodging $925 3 payments
  4. Food and Beverage $490 8 payments
Products named General payments · program years 2019–2025
  1. PTEYE PARATHYROID DETECTION SYSTEM $9,156 6 payments
  2. NIM $6,711 10 payments
  3. Parsabiv $5,000 1 payment
  4. NIM Vital $4,500 5 payments
  5. NIM-RESPONSE $4,080 3 payments
  6. PROPEL $72 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,970 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Otolaryngology: 297

Drug cost

$30

Median for Otolaryngology: $6,314

Branded share of claims

100%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$30,515

Medicare's payments for the services billed

Medicare patients

90

Average age 71

Services billed

148

67 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 34%
Chronic kidney disease 33%
Ischemic heart disease 31%
Depression 30%
Osteoporosis 27%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record